Chemotherapy News and Research

Latest Chemotherapy News and Research

BioAlliance Pharma awarded €2 million in funding to study Lauriad mucoadhesive technology

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, today announced the award of €2 million in funding over 30 months from the « Fond Unique Interministériel » (a French program supporting collaborative research projects) including an amount of €743,000 specifically allocated to BioAlliance Pharma.

5 Mar 2011

Medifocus to present on Microfocus APA-1000 at Annual National Interdisciplinary Breast Center Conference

Medifocus Inc. is pleased to announce that two clinical presentations of the Company's breast cancer treatment system, the Microfocus APA-1000, will be made at the 21st Annual National Interdisciplinary Breast Center Conference , March 12-16, 2011 in Las Vegas , NV.

5 Mar 2011

BNCT treatment proves effective in treating recurrent head, neck cancer

Biologically targeted BNCT treatment is based on producing radiation inside a tumour using boron-10 and thermal neutrons. Boron-10 is introduced into cancer cells with the help of a special carrier substance (phenylalanine), after which the tumour is irradiated with lowenergy neutrons.

5 Mar 2011

New research into drugs to prevent brain tumours in children wins vital funding

New research into drugs which could prevent the return of persistent brain tumours in children has won vital funding from two major brain tumour charities.

5 Mar 2011

BCAN to host new forum on March 12 to raise awareness about bladder cancer

Bladder cancer is the fifth most commonly diagnosed cancer, and there are more than 600,000 survivors in the United States, yet most people know nothing about it.

4 Mar 2011

$Chemotherapy, endocrine therapy may increase risk of bone fractures in breast cancer survivors$

Chemotherapy, endocrine therapy may increase risk of bone fractures in breast cancer survivors

The combined effects of chemotherapy and endocrine therapy may increase the risk of bone fractures in breast cancer survivors.

4 Mar 2011

U.S. Representatives, Gene Green introduce bipartisan bill to ensure Medicare reimbursement

U.S. Representatives Ed Whitfield and Gene Green today introduced H.R. 905.

4 Mar 2011

Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL

Allos Therapeutics, Inc. today announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment (SPA) process for the design of the Company's Phase 3 clinical trial of FOLOTYN® (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL).

4 Mar 2011

Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

Infinity Pharmaceuticals, Inc. today announced the initiation of a randomized, double-blind Phase 2 clinical trial to evaluate the safety and efficacy of IPI-926 compared to placebo in patients with metastatic or locally advanced, inoperable chondrosarcoma. The trial is expected to enroll over 100 patients worldwide.

3 Mar 2011

Eisai announces publication of Halaven Phase III study results against breast cancer in The Lancet journal

Eisai announced today that results from the global Phase III clinical study "EMBRACE" will be published online in The Lancet.

3 Mar 2011

Lixte receives $244,479.25 U.S. government grant for QTDP program

Lixte Biotechnology Holdings announced today that the company has received a $244,479.25 grant under the Qualifying Therapeutic Discovery Project.

3 Mar 2011

Scientists discover genetic process that may allow ovarian cancer to resist chemotherapy

York University researchers have zeroed in on a genetic process that may allow ovarian cancer to resist chemotherapy.

3 Mar 2011

Mathematical model predicts lifespan of stem cells

When patients receive a bone marrow transplant, they are getting a new population of hematopoietic stem cells. Fresh stem cells are needed when a patient is low on red blood cells, as in anemia, or white blood cells, which can be caused by cancer or even cancer treatments such as irradiation or chemotherapy. The problem is that a bone marrow transplant might not succeed because the transplanted stem cells don't live long enough or because they proliferate too well, leading to leukemia.

2 Mar 2011

Additional pathology tests can improve survival rates in patients with oesophageal cancer

A University of Adelaide medical researcher says current treatment for people diagnosed with oesophageal cancer could be improved with additional pathology tests.

2 Mar 2011

NCI sponsors multi-center phase 2 study of entinostat-anastrozole combination in triple negative breast cancer

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response.

2 Mar 2011

Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin in combination with chemotherapy for the treatment of newly diagnosed systemic anaplastic large cell lymphoma patients.

1 Mar 2011

ADC announces RNAscope technology clinical study results for HPV-associated head and neck cancers

Advanced Cell Diagnostics, Inc. today announced the results of its clinical study utilizing RNAscope technology to detect human papillomavirus E6/E7 mRNA in routine clinical specimens of head and neck cancer.

From Advanced Cell Diagnostics 1 Mar 2011

Chromosomally unstable bowel cancer cells more resistant to chemotherapy treatments, targeted drugs

Cancer Research UK scientists have made an important step towards developing personalised bowel cancer treatment by identifying which tumours are more likely to become drug resistant, according to research published in Cancer Research today.

1 Mar 2011

Leptin receptor antagonist peptide demonstrates efficacy against triple negative breast cancer

A new peptide developed by researchers in Temple University's College of Science and Technology has demonstrated efficacy against triple negative breast cancer.

1 Mar 2011

New personalized therapy fools cancer cells into killing themselves

A Wayne State University School of Medicine physician-researcher has developed a personalized therapy to treat a wide range of cancers. The treatment is based on a naturally occurring human enzyme that has been genetically modified to fool cancer cells into killing themselves.

1 Mar 2011

Chemotherapy News and Research

Latest Chemotherapy News and Research

BioAlliance Pharma awarded €2 million in funding to study Lauriad mucoadhesive technology

Medifocus to present on Microfocus APA-1000 at Annual National Interdisciplinary Breast Center Conference

BNCT treatment proves effective in treating recurrent head, neck cancer

New research into drugs to prevent brain tumours in children wins vital funding

BCAN to host new forum on March 12 to raise awareness about bladder cancer

Chemotherapy, endocrine therapy may increase risk of bone fractures in breast cancer survivors

U.S. Representatives, Gene Green introduce bipartisan bill to ensure Medicare reimbursement

Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL

Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

Eisai announces publication of Halaven Phase III study results against breast cancer in The Lancet journal

Lixte receives $244,479.25 U.S. government grant for QTDP program

Scientists discover genetic process that may allow ovarian cancer to resist chemotherapy

Mathematical model predicts lifespan of stem cells

Additional pathology tests can improve survival rates in patients with oesophageal cancer

NCI sponsors multi-center phase 2 study of entinostat-anastrozole combination in triple negative breast cancer

Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL

ADC announces RNAscope technology clinical study results for HPV-associated head and neck cancers

Chromosomally unstable bowel cancer cells more resistant to chemotherapy treatments, targeted drugs

Leptin receptor antagonist peptide demonstrates efficacy against triple negative breast cancer

New personalized therapy fools cancer cells into killing themselves

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in